- Home >
- Clinicals Trials >
- AV-299-23-301
Retour à la liste des essais cliniquesENT/Head and Neck Cancers
AV-299-23-301
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)
- Ouvert à Paris depuis le : 05/12/2024
- Public cible : Adult
- Phase : Phase III
Description de l'essai
To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Overall survival (OS), defined as the time from the date of randomization to the date of death for any cause.
Url of the trialInvestigateur principal
